Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2020; 8(15): 3259-3266
Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3259
Published online Aug 6, 2020. doi: 10.12998/wjcc.v8.i15.3259
Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding – ovulation dysfunction patients
Lu Wang, Hai-Yun Guan, He-Xia Xia, Xiu-Ying Chen, Wei Zhang, Department of Reproductive Endocrinology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China
Author contributions: Wang L and Guan HY performed the majority of experiments and wrote the manuscript; Xia HX designed the study and corrected the manuscript; Chen XY contributed to data analysis; Zhang W was responsible for designing and performing the study, manuscript reviewing and approval of the final version; all authors have read and approve the final manuscript.
Supported by Abbott (32F Crio's Plaza , 388 West Nanjing Road, Shanghai, China), No. A14-390 .
Institutional review board statement: The study protocol was approved by the Ethics Committee, Obstetrics and Gynecology Hospital of Fudan University (Shanghai).
Informed consent statement: Written informed consent was obtained from each participant.
Conflict-of-interest statement: Dr. Zhang W is the Principle Investigator of the present study, which was supported by grants A14-390 from Abbott (32F Crio's Plaza, 388 West Nanjing Road, Shanghai, China).
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Wei Zhang, MD, Professor, Department of Reproductive Endocrinology, Obstetrics and Gynecology Hospital of Fudan University, No. 419 Fangxie Road, Shanghai 200011, China. zhangwei623@hotmail.com
Received: March 4, 2020
Peer-review started: March 4, 2020
First decision: April 14, 2020
Revised: June 2, 2020
Accepted: June 23, 2020
Article in press: June 23, 2020
Published online: August 6, 2020
Peer-review started: March 4, 2020
First decision: April 14, 2020
Revised: June 2, 2020
Accepted: June 23, 2020
Article in press: June 23, 2020
Published online: August 6, 2020
Core Tip
Core tip: The normal interval of menstrual-cycle is typically 21 to 35 d and duration of normal menstrual flow is generally 5 d. Abnormal uterine bleeding continues to pose significant physical and financial burdens on patients. In this study, we analyzed the data of 114 women with abnormal uterine bleeding - ovulation dysfunction (AUB-O) who were treated with dydrogesterone 10 mg from day 16 to day 25 of each cycle, consecutively for at least 3 cycles. It is suggested that dydrogesterone therapy was effective in achieving menstrual-cycle regularization for Chinese patients with AUB-O.